SCHEMBL24330033

SCHEMBL24330033

O=C(NN1C(=O)c2cccc3cccc1c23)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTRB1 P17538 1/20 0.47
▸ KDM4E B2RXH2 7/20 0.46
▸ ALDH1A1 P00352 7/20 0.46
▸ POLB P06746 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.44
▸ KMT2A Q03164 4/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ HPGD P15428 3/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ TPSAB1 Q15661 1/20 0.43
▸ TPSD1 Q9BZJ3 1/20 0.43
▸ TPSG1 Q9NRR2 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ GAA P10253 2/20 0.42
▸ CASP1 P29466 2/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ CASP3 P42574 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29583059 1.00 CTRB1 (0.47) CTRB1KDM4EALDH1A1POLBNPSR1
SCHEMBL5638173 0.83 MEN1 (0.60) CTRB1KDM4EALDH1A1POLBNPSR1
Carbamic Acid SCHEMBL29087081 0.79 MEN1 (0.56) CTRB1KDM4EALDH1A1POLBNPSR1
SCHEMBL26691523 0.79 KDM4E (0.52) KDM4EALDH1A1POLBKMT2AMEN1
SCHEMBL19325396 0.77 TACR1 (0.54) —
SCHEMBL25583410 0.74 CTRB1 (0.60) CTRB1KDM4EALDH1A1POLBNPSR1
SCHEMBL7828642 0.71 HDAC3 (0.51) KDM4EALDH1A1NPSR1L3MBTL1SMN1; SMN2
SCHEMBL29066255 0.70 KMT2A (0.51) KDM4EALDH1A1POLBKMT2AMEN1
SCHEMBL7423680 0.70 L3MBTL1 (0.52) ALDH1A1POLBL3MBTL1SMN1; SMN2GAA
SCHEMBL876242 0.70 CASP1 (0.48) ALDH1A1POLBSMN1; SMN2GAACASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 — — US disclosed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 — — US disclosed
WO-2022081928-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS CRBN, CDR2, MDM2 CTRB1 180/4885KDM4E 2875/4885ALDH1A1 4099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback